HOME >> MEDICINE >> NEWS
Further Evidence On The Effect Of The UK Cervical Screening Programme

(Effect of screening on cervical cancer mortality in England and Wales: analysis of trends with an age period cohort model)

In this week's BMJ a paper written by Dr Peter Sasieni and Joanna Adams from the Imperial Cancer Research Fund supports recent findings of a beneficial effect of the national cervical screening programme. The authors say that before the relaunch of the programme in 1988 screening had a minimal effect on mortality, but since its relaunch screening appears to have reduced cervical cancer mortality by over 60 per cent in those aged under 55 years (up until 1997). They estimate that 1300 lives were saved in 1997 by screening in previous years.

Contact:

Dr Peter Sasieni, Senior Scientist, Department of Mathematics, Statistics and Epidemiology, Imperial Cancer Research Fund, London comms@icrf.icnet.uk Further Evidence on the Effect of the National Cervical Screening Programme In this week's BMJ, researchers support recent findings of a beneficial effect of the national cervical screening programme. The authors say that since its relaunch screening appears to have reduced cervical cancer mortality by over 60 per cent in those aged under 55 years.


'"/>

Contact: Jill Shepherd
jshepherd@bma.org.uk
44-171-383-6529
BMJ-British Medical Journal
7-May-1999


Page: 1

Related medicine news :

1. Further evidence reveals the association between periodontal disease and coronary artery disease
2. Further evidence showing treatment benefits of beta interferon for MS
3. Further studies comparing rehydration therapies would waste resources, say researchers
4. Further evidence for effectiveness of nevirapine in reducing mother-to-child HIV-1 transmission
5. Further evidence that HRT does not protect against cardiovascular disease
6. Further evidence linking suicide risk to family history (p 1126)
7. Further evidence of increase in allergic disease in western countries
8. Holding Policy Is Cost-Effective Way To Further Protect Blood Plasma Supply From HIV And Other Infections
9. Jefferson Physician Warns Further Study Of DHEAs Safety Needed
10. Evidence indicates cancer patients unable to intentionally postpone death for significant events
11. Not guilty! Evidence exonerates 328, but many still falsely imprisoned

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Further Evidence The Effect The Cervical Screening Programme

(Date:11/26/2014)... 2014 GI for Life announced today, ... in prices of their popular nutritional supplements: ColoVite ... . Discounts of 40% will be offered for ... Life’s proprietary ColoVite supplement is a scientifically formulated vitamin ... health. One easy-to-take colon vitamin with ALL the nutrients ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 Call 866-997-4948 ... requirements or email the details on sales(at)researchmoz(dot)us , ... and drug discovery market 2014" with deep study of ... the result of high blood sugar. The global glucose ... linked to the growing number of diabetics in the ...
(Date:11/26/2014)... News Facts , Lexmark’s Perceptive ... 2014 in Chicago. The company will demonstrate solutions ... photos, videos and documents found throughout the healthcare ... more about these innovative medical content management solutions ... – that enable more informed clinical decisions, promote ...
(Date:11/26/2014)... TUESDAY, Nov. 25, 2014 (HealthDay News) -- Teens ... likely to abuse those drugs than other teens, ... the need to conduct substance abuse assessments on ... researchers said. "Prescribers and parents don,t realize ... a professor at the University of Michigan School ...
(Date:11/26/2014)... need to take an active role in protecting their ... must make sure sports-playing teens have the right protective ... the American Migraine Foundation and a professor of medicine ... Ariz. in an American Migraine Foundation, said in a ... teens sports needs to have appropriate training. Teen sports ...
Breaking Medicine News(10 mins):Health News:GI For Life Slashes Prices by 40% on Liposomal Vitamin D3 and ColoVite Colon Health Formula for a Limited Time 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 2Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 3Health News:Teens Given Anxiety, Sleep Meds May Be at Risk for Drug Abuse 2Health News:Parents Need to Take Lead on Teen Concussion Prevention 2
(Date:11/26/2014)... and LONDON , Nov. 25, ... AstraZeneca (NYSE: AZN ) today announced that AMAGINE-2 ... doses of brodalumab in more than 1,800 patients with moderate-to-severe ... Stelara ® (ustekinumab) and placebo at week 12. Brodalumab ... analysis group were each shown to be superior to Stelara ...
(Date:11/26/2014)... China , Nov. 26, 2014 / -- China Nepstar Chain ... "Company"), a leading retail drugstore chain in ... operated stores, today announced the appointment of Ms. ... Officer, effective immediately. Ms.Zhang has over ... joined Nepstar in March 1999. Prior to Ms. Zhang,s ...
(Date:11/24/2014)... -- Juno Therapeutics today announced that the FDA ... JCAR015 chimeric antigen receptor product candidate.  The designation ... B-cell acute lymphoblastic leukemia and was filed by ... where Phase 1 clinical trials are currently underway. ... news for patients who may benefit from the ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 2China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 3Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 3
Cached News: